This preprint reports a double-blind, randomized clinical trial of 62 patients to assess the efficacy of hydroxychloroquine (HCQ) in mild COVID-19. Patients in the treatment arm received 400 mg HCQ per day for 5 days. Fever and cough resolved on average 1 day earlier with HCQ, although the distribution of symptomatic patients at day 0 was not even between groups. No patients receiving HCQ progressed to severe disease, whereas 4 of 31 patients in the control arm progressed. Few clinical data and no viral load measurements were reported, limiting the conclusions that can be drawn from this trial. This study suggests relative efficacy for patients with mild disease and warrants larger clinical trials, but the effects of HCQ on patients with more severe COVID-19 remain unknown.
Chen, Z. et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Preprint at medRxiv https://doi.org/10.1101/2020.03.22.20040758 (2020)
The authors declare no competing interests.
About this article
Cite this article
Levantovsky, R., Vabret, N. Hydroxychloroquine: small effects in mild disease. Nat Rev Immunol 20, 350 (2020). https://doi.org/10.1038/s41577-020-0315-4
Food and Chemical Toxicology (2021)
Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment
Mediators of Inflammation (2020)
Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins
Journal of Biomolecular Structure and Dynamics (2020)